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Attenuation of Human Immunodeficiency Virus Type 1
Cytopathic Effects by Replacing a 424-bp Region of 
Envelope from a Noncytopathic Biological Clone
SERENE E. FORTE, MOHAN SOMASUNDARAN, and JOHN L. SULLIVAN
ABSTRACT
We analyzed the env genes of cytopathic and noncytopath ic biological clones derived from two HIV-1-infected
children with discordant clinical courses. Chimeric viruses were constructed by switching env regions from
V2 through V3 of the biological clones with the corresponding region from the molecular clone NL4-3. These
HIV-1 chimeric viruses exhibited similar replication kinetics as well as syncytium-inducing abilities. The
chimeric virus containing the env region of noncytopathic biological clone, GC6 8-4, was noncytopathic in an
in vitro cell-killing assay, while the chimeric virus containing the env region of cytopathic biological clone,
HC4, was cytopathic in the in vitro cell-killing assay. These studies suggest the presence of a cytopathicity de-
terminant that maps to the envelope sequences contained within the downstream region of V2 and within the
V3 region (nucleotide position 6822 to nucleotide position 7250, based on NL4-3 sequence).
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INTRODUCTION
T HE EN TR Y of human immunodeficie ncy virus type 1 (HIV-1) into cells is mediated by the envelope glycoprotein. HIV-
1 strains differ in their ability to infect specific cell types and
can be characterized in vitro according to their ability to repli-
cate in macrophages and established T-cell lines as well as by
their ability to induce cytopathic effects. Two groups of iso-
lates have been described: those that are capable of replicating
in established T-cell lines (T-cell tropic) and those that infect
primary macrophages (M-topic). T-cell tropic isolates replicate
more rapidly and to higher levels in primary lymphocytes
(rapid/high) than M-tropic isolates, which replicate slowly and
to lower levels in primary lymphocytes (slow/low).1–4 Many
isolates that infect T cells are able to induce syncytia and are
termed syncytium-induc ing (SI), whereas most M-tropic iso-
lates are non-syncytium- inducing (NSI).
Recently, new discoveries have shown that chemokine re-
ceptors are important cofactors for entry of HIV-1 into cells.5
CXCR4 mediates viral entry into CD4-positive T-cell lines and
CCR5 mediates entry into macrophages. 6–10 Dual tropic HIV-
1 strains have been identified that can use either one of these
receptors to gain entry into cells.6 ,8
The hallmark of HIV-1 infection is the progressive destruc-
tion of CD4 T cells in vivo.11,12 Macrophage tropic NSI iso-
lates are preferentially transmitted and are present throughout
the length of infection. 13–15 The emergence of T-cell tropic SI
isolates correlates with the decrease of CD4 lymphocytes and
progression of HIV-1 infection to AIDS.4,16 However, this
switch to T-cell tropic SI isolates is not necessary for T-cell de-
pletion and progression to AIDS, especially in vertical HIV-1
infection. 17,18
There is no clear correlation between when an infant is in-
fected and disease progression. It has been reported that an as-
sociation exists between in utero infection, high viral load in
the early neonatal period, and rapid disease progression. 19 How-
ever, plasma RNA levels in infants infected in utero or in the
intrapartum period are not easily separable. While it is true that
most infants with high viral burdens will exhibit disease pro-
gression, we have followed vertically infected children for sev-
eral years with extremely high viral loads and normal CD4
counts. 17,18 While disease progression following vertical infec-
tion may be variable with observable differences in the occur-
rence of illness and survival times,20 by and large vertically in-
fected children experience a more rapid clinical course than
adults. A number of factors are likely to be responsible for the
observed variability in clinical course. These include the route
of perinatal HIV-1 transmission, 21 the viral burden, 22,23 the bi-
ological phenotype, 15,24–26 and host factors including both cel-
lular and humoral immune responses. 27–29
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The molecular mechanism(s) of HIV-1-induced  cell lysis re-
mains unclear and is likely to be multifactorial. Differences in
HIV-1 viral tropism, phenotype, and replication kinetics have
been assigned to the envelope surface glycoprotein. 30,31 Along
with these properties, studies of mutant HIV-1 viruses have pro-
vided evidence that a major determinant for single cell killing
maps to the viral envelope glycoproteins. 32–34 Cao et al.35 de-
scribed an inducible system to examine envelope-media ted sin-
gle cell lysis. Their studies demonstrated that the ability of HIV-
1 envelope glycoproteins to mediate membrane fusion was
obligatory for both syncytium formation and single cell lysis.
Previously, we described functional HIV-1 biological clones
that were isolated from two infected children with high viral
loads in vivo18 who had discordant clinical courses. The ab-
solute CD4 cell counts of HIV-1-seroposi tive pediatric patients
A and D, at the time of virus isolation, were 2312 and 64
counts/mm ,3 respectively. The primary HIV-1 isolate, A, ob-
tained from patient A at 47 months of age, was NSI and HIV-
1 isolate, D, obtained from patient D at 36 months of age, was
SI. Patient D has subsequently succumbed to AIDS, while pa-
tient A remained asymptomatic (and is currently on combina-
tion antiretroviral therapy). Multiple biological clones were ob-
tained from HIV-1 isolates A and D. All the biological clones
from isolate A were NSI and all the biological clones from iso-
late D were SI in MT-2 cells. Representative biological clones,
GC6 8-4 (derived from isolate A obtained from patient A) and
HC4 (derived from isolate D obtained from patient D) grew to
the highest titer and were selected for further characterization. 18
These clones exhibited similar replication kinetics but differed
in syncytium-induc ing ability: biological clones GC6 8-4 and
HC4 are NSI and SI, respectively. Furthermore, the biological
clones GC6 8-4 and HC4 differed markedly in in vitro cell-
killing assays: GC6 8-4 was noncytopathic and HC4 was cyto-
pathic.18
To assess the relationship between envelope gene sequences
and cell killing, we analyzed the envelope gene of biological
clones GC6 8-4 and HC4. Chimeric viruses were constructed
by switching the envelope sequences contained within the
downstream region of V2 and within the V3 region of each of
the biological clones with the corresponding region from the
molecular clone NL4-3. These chimeric viruses exhibited sim-
ilar replication kinetics as well as syncytium-indu cing abilities.
The only difference was in their ability to induce cell killing.
These studies provide evidence that in certain viral variants,
HIV-1-induced  cytopathicity maps to the envelope sequences
contained within the downstream  region of V2 and within the
V3 region (StuI at position 6822 to NheI at position 7250 based
on NL4-3 nucleic acid sequence 36).
MATERIALS AND METHODS
Patients
Patient A was clinically asymptomatic when the virus was
isolated and remains so 7 years later. At the time of viral iso-
lation, patient A was 47 months old, with normal CD4 counts
of 2312/mm.3 Unexpectedly, peripheral viremia in this child
was very high as determ ined by serum  HIV-1 p24 antigen lev-
els (1773 pg/ml) and by plasma viral RNA copies (280,000/ ml).
Since the original viral isolate was obtained, Patient A has main-
tained normal CD4 T-cell numbers and is currently on combi-
nation antiretroviral therapy. Patient D had AIDS at the time of
viral isolation. The child was 36 months old with very low CD4
T cell counts (64/mm3).18
Virus culture
Peripheral blood mononuclear cells (PBMC) from seroneg-
ative individuals were infected with biological clones, GC6 8-
4 and HC4.18 On days 3 and 5 of viral infection, culture su-
pernatants were monitored for HIV-1 p24 antigen production
by ELISA. On day 5 postinfection, 107 cells were harvested
and genomic DNA was extracted.
DNA isolation
PBMC (107) from cultures infected with biological clones,
GC6 8-4 and HC4, were pelleted and washed twice with phos-
phate-buffered saline (PBS). Genomic DNA was prepared by
resuspending the cell pellets in 5 ml lysis buffer (10 mM
Tris–HCl, 400 mM NaCl, 2 mM EDTA, pH 8.2) to which
sodium dodecyl sulfate (SDS) (final concentration 0.7%) and
proteinase K (1.7 mg) were added. The genomic DNA prepa-
ration was incubated at 37°C overnight. Following this incu-
bation, 1.6 ml saturated NaCl was added, mixed, and cen-
trifuged at 2500 rpm for 15 min. To the supernatant, 7 ml of
isopropanol was added to precipitate the DNA. The DNA was
pelleted by centrifugation, resuspended in 30 m l TE, and stored
at 2 20°C.
PCR amplification of env region
Approximately  200 ng of genom ic DNA was used as a tem-
plate for amplification of a 3.0-kb product of HIV-1 proviral
sequence containing the entire coding region for gp160. The re-
action mixture contained 10 m l GeneAmp PCR Buffer II (50
mM KCl, 10 mM Tris–HCl); 2.5 mM MgCl2 ; 200 m M each of
dATP, dCTP, dGTP, and dTTP; 10 pmol each of primer I5-1
(5 9 -CAGAATTGGGTGTCGACATAGCAG-3 9 ) and MN12
(5 9 -CACTTGCCACCCATCTTATAGGAAAATCCTTTC-
CAAGCC-3 9 ) in a final volume of 90 m l. Primers I5-1 and MN-
12 anneal at positions 5774–5797 and 8762–8801, respectively,
based on published NL4-3 nucleotide positions. 36 Polymerase
chain reactions (PCR) were completed in an automated Perkin-
Elmer (GeneAmp 9600) thermal cycler programmed for the fol-
lowing: denaturation at 94°C for 3 min, followed by the addi-
tion of Perkin Elmer AmpliTaq (2.5 U in 10 m l) during 87°C
hold (“hot start”). The reactions were subjected to 30 cycles at
94°C for 1 min, 55°C for 1.5 min, and 72°C for 3 min. A final
extension step at 72°C for 10 min was added after the last am-
plification cycle.
Molecular cloning of env region into an 
expression vector
To screen for the appropriate sized amplicon, 10 m l of the
final PCR amplification was resolved by electrophoresis on a
0.8% agarose gel. The remaining 90 m l of the reaction was phe-
nol-chloroform extracted, ethanol precipitated, resuspended in
15 m l of water, and resolved by electrophoresis on a 0.8%
agarose gel. The 3-kb DNA fragm ent was excised from the gel,
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purified by Elu-Quick (Schleicher & Schuell, Keene, NH), re-
suspended in water, and stored at 2 20°C until further use. The
purified product was ligated into pBluescript (Stratagene, La
Jolla, CA) and 10 m l of the ligation reaction was used to trans-
form DH5 a bacterial cells. Transformed colonies were color 
selected on ampicillin, IPTG (isopropyl- b -D-thiogalactopyra-
noside), X-gal (5-bromo-4-chlo ro-3-indoyl- b -D-galactopyra-
noside) plates. White colonies were chosen and amplified in
culture. Minipreps were performed from the overnight cultures.
The miniprep DNA was screened for the appropriate sized in-
sert by restriction digest and electrophoresis on a 0.8% agarose
gel.
DNA sequencing of full length env region
The double-stranded plasmid DNA was sequenced in both
the forward and reverse directions with primers that spanned
the entire env regions overlapping every 200 bps (primer se-
quences available upon request). Of double-stranded DNA tem-
plate 1 m g/ m l was added to 8 m l terminator premix (A-dye ter-
minator, C-dye terminator, G-dye terminator, T-dye terminator,
dITP, dATP, dCTP, dTTP, Tris–HC1, pH 9.0, MgC12, thermal
stable pyrophosphatase, and AmpliTaq DNA polymerase FS),
10 pmol of primer, and water to a final volume of 20 m l. DNA
sequencing was performed in an automated Perkin-Elm er ther-
mal cycler (GeneAmp 9600) programm ed for 30 cycles of de-
naturation at 94°C for 1 min, primer annealing at 55°C for 1.5
min, and extension at 72°C for 3 min. The reaction mixture was
ethanol precipitated to remove unincorporated deoxynucleoside
triphosphate and oligonucleotides, and then vacuum dried. The
dye-deoxy-labeled  sequencing reaction mixes were resolved by
electrophoresis on a 6% polyacrylamide gel and analyzed with
an autom ated DNA sequenator (model 373A, Applied Biosys-
tem, Inc., Foster City, CA). Individual sequences were assem -
bled by using the Sequencher program (Gene Codes Corp, Ann
Arbor, MI). Sequences were determined for both strands of
DNA and were aligned by the methods of Lamers et al.37 at
Gene Genie, Inc (Thibodaux, LA).
Plasmids
Plasmid pNL4-3, containing a chimeric HIV-1 provirus, was
obtained from the AIDS Research and Reference Reagent Pro-
gram, Rockland, MD. The subclones, p83-2 and p83-10, the 5 9
and 3 9 half of NL4-3, respectively, were kindly provided by R.
Desrosiers. 38
PCR of the StuI to NheI region of env
Since GC6 8-4 and HC4 envelope sequence lack the NHeI
sites but contain the StuI sites, this region was obtained by means
of PCR with StuI primer (5 9 -ATTACACAGGCCTGTCCA-
CAGGTA-3 9 ) and NheI primer (3 9 -TTCTCTTAATTTGCTA-
GCTATCTG-5 9 ). Approximately 200 ng of DNA was used as
a template for amplification of a 424-bp product of HIV-1 env
sequence contained within the downstream region of V2 and
within the V3 region. The reaction mixture contained 10 m l Ge-
neAmp PCR Buffer II (50 mM KCl, 10 mM Tris–HCl, pH 8.3),
2.5 mM MgCl2, 200 m M each of dATP, dCTP, dGTP, and dTTP,
and 10 pmol each of primer, in a final volume of 90 m l. “Hot
start” PCR reactions were completed in an automated Perkin-
Elmer (GeneAmp 9600) thermal cycler programmed for denat-
uration at 94°C for 3 min, followed by the addition of Ampli-
Taq (2.5 U in 10 m l) during 87°C hold. The reaction mixtures
were subjected to 30 cycles at 94°C for 1 min, 55°C for 1.5 min,
and 72°C for 3 min. A final extension step at 72°C for 10 min
was added after the last amplification cycle.
Molecular cloning of NL4-3 chimeric constructs, 
p83-SFG and p83-SFH
From the PCR reaction 10 m l was resolved by electrophore-
sis on a 1% agarose gel to screen for the appropriate molecu-
lar weight amplicon. The remaining 90 m l of the PCR reaction
mixture was ethanol precipitated and resuspended in 15 m l of
water and stored at 2 20°C. The 424-bp DNA fragment was gel
purified by Elu-Quick, phenol-chlorofor m extracted, ethanol
precipitated, and resuspended in water. The purified product
was cloned into p83-10 38 by appropriate restriction sites (StuI
at position 6822 and NheI at position 7250 based on published
NL4-3 nucleotide sequence). 38 Aliquots (10 m l) of the ligation
product was used to transform competent DH5 a bacterial cells.
Colonies were chosen at random  and amplified overnight in 
5 ml LB broth containing ampicillin. A small scale plasmid
preparation was performed to recover DNA. Of the plasmid
preparation 10 m l was digested with appropriate restriction en-
donuclease, and the presence of an insert was screened by elec-
trophoretic resolution on a 1% agarose gel.
Cell culture
CEM 3 174 cells and Jurkat cells were maintained in medium
containing RPMI-1640 (GIBCO Laboratories, Grand Island,
NY) supplemented with 10% fetal calf serum (FCS) (GIBCO
Laboratories, Grand Island, NY). Jurkat-CCR5 cells (kindly
provided by M. Emerman) were maintained in RPMI-1640/10%
FCS containing 0.2 m g/ml of puromycin. PBMC and CD4 
T cells were cultured at 2 3 106 cells/ml in RPMI-1640/10%
FCS containing 10 units/ml of recom binant human interleukin-
2 (Boehringer-M annheim , Indianapolis, IN).
Transfections
Transfections were carried out following the procedure described
by Gibbs et al.38 Briefly, just prior to transfection, 3 m g of DNA
was added stepwise in five aliquots with gentle vortexing to 
1.4 ml of Dulbecco modified Eagle medium (DMEM) DEAE-
Dextran solution (DMEM containing 125 m g/ml of DEAE-
Dextran in 50 mM Tris, pH 7.3). In a 15-ml conical tube, 6 ml
of CEM 3 174 was pelleted containing 0.5–0.8 3 106 cells/ml,
which were split the night prior. The cells were washed twice
with 5 ml of serum-free DMEM and resuspended in 1.4 ml of
DNA–DMEM–DEAE–Dextran solution. The cell DNA–DMEM
mixture was incubated at 37°C for 1 h. After incubation, the cells
were pelleted and washed with 5 ml serum-free DMEM. Cells
were resuspended in 6 ml RPMI-1640/10% FCS and incubated
at 37°C. Supernatant p24 antigen activity was monitored every
2–3 days. Cells were split as needed 1:2 or 1:3 twice weekly.
Viral phenotype of HIV-1 chimeric viruses
Chimeric viruses (SF-G 1, 3, 4, 5 and SF-H 2, 3, 4, 5) were
phenotyped on MT-2 cells for their ability to replicate and form
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syncytia following a previously published protocol. 39 The pro-
tocol was modified to determine viral replication in MT-2 cells
using antigen capture ELISA to measure HIV-1 p24 gag pro-
tein in cell-free supernatants. 17 Similarly, chimeric viruses were
phenotyped on Jurkat cells and Jurkat-CCR5 cells for their abil-
ity to form syncytia and to replicate.
Infection of Jurkat-CCR5 cells with chimeric viruses,
SF-G1 and SF-H2
Since both SF-G1 and SF-H2 chimeric viruses infected and
replicated in Jurkat-CCR5 T cells and not in Jurkat T cells, 
Jurkat-CCR5 cells were infected with HIV-1 chimeric viruses
according to previously described methods.18 HIV-1 infected
and uninfected Jurkat-CCR5 cells were cultured at 0.5 3 106
cells/ml in RPMI-1640/10% FCS containing 0.2 m g/ml of
puromycin.
Infection of primary PBMC with HIV-1 
chimeric viruses
Of viral p24 from chimeric viruses obtained by transfections 50
ng/ml was used to infect PBMC. Briefly, normal PBMC from
HIV-1-seroneg ative donors were phytohem agglutinin (PHA)
stimulated for 3 days and infected with HIV-1 chimeric viruses,
SF-G1 and SF-H2, according to previously described meth-
ods.18 HIV-1-infected and uninfected PBMC were cultured at
2 3 106 cells/ml in RPMI-1640/10% FCS containing 10
units/ml of recombinant human interleukin-2.
Depletion of CD8 T cells
PBMC were isolated by Ficoll density and CD8 T cells were
depleted using anti-CD8 antibody-coated magnetic beads (Dy-
nal, Inc., Lake Success, NY) according to manufacturer’ s pro-
tocol. The supernatant containing CD4 T cells was centrifuged
and the cell pellet was resuspended in RPMI-1640/10% FCS
with 10 units/ml of interleukin-2.
Infection of CD4 T cells with HIV-1 chimeric viruses,
SF-G1 and SF-H2
CD4 T cells were PHA stimulated overnight and infected
with HIV-1 chimeric viruses, SF-G1 and SF-H2, according to
previously described methods.18 HIV-1-infected  and uninfected
CD4 T cells were cultured at 2 3 106 cells/ml in RPMI-
1640/10% FCS with 10 units/ml of interleukin-2.
Assessment of HIV-1-induced cytopathic effects
HIV-1-induced  cytopathic effects by the chimeric viruses, SF-
G1 and SF-H2, were determined by evaluating cell viability us-
ing trypan blue dye exclusion.
Measurement of cell surface CD4 and CD8 expression
Cell surface CD4 and CD8 expression was measured by flow
cytometry. Briefly, 107 cells from either infected or uninfected
T-cell cultures were washed with cold PBS containing 1% azide
and incubated for 30 min on ice with a mixture of fluorescein-
labeled anti-CD4 monoclonal antibody and phycoerythrin-la-
beled anti-CD8 monoclonal antibody (Becton-Dicki nson, San
Jose, CA). The cells were washed with PBS containing 1%
azide and fixed for 10 min in 0.2% paraformaldehyd e in PBS
and analyzed by FACscan flow cytometer (Becton-Dicki nson,
San Jose, CA). Phycoerythrin- and fluorescein-labele d mouse
gamma-globulins were used as negative stains for controls.
Determination of HIV-1 proviral copies
To determine the number of proviral copies of HIV-1 viral
DNA, PCR was performed on lysates of serially diluted CD4
T cells infected with chimeric viruses, SF-G1 and SF-H2, us-
ing the Roche Amplicor HIV-1 test kit following the previously
published method.40 Briefly, a region of HIV-1 gag gene was
amplified using biotinylated SK431/SK462 primer pairs in an
automated Perkin Elmer (GeneAmp 9600) thermocycler. The
cycling parameters were as follows: five cycles of denaturation
at 95°C for 10 sec, annealing at 55°C for 10 sec, and extension
at 72°C for 10 sec; followed by 30 cycles of denaturation at
90°C for 10 sec, annealing at 60°C for 10 sec, and extension
at 72°C for 10 sec, and an additional extension at 72°C for 5
min. The amplicons were captured in wells coated with the
probe and detected by ELISA using avidin-conjugated  horse-
radish peroxidase as a secondary marker.
Measurement of viral replication
To measure HIV-1 replication in infected PBMC, Jurkat-
CCR5 cells, and CD4 T-cell cultures, cell-free culture super-
natants were assayed for HIV-1 p24 gag protein using an anti-
gen capture ELISA.
RESULTS
Derivation of HIV-1 biological clones and 
chimeric viruses
The derivation of HIV-1 biological clones and NL4-3
chimeric viruses from viral isolates obtained from patients A
and D are delineated below :
Patient AR isolate A R clone GC6 8-4 R chimeric GC68-
4/NL4-3 (SF-G1)
Patient D R isolate DR clone HC4R chimeric HC4/NL4-3
(SF-H2)
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FIG. 1. Alignment of variable regions of the envelope gene of HIV-1 biological clones, GC6 8-4 and HC4, and T-cell and
macrophage tropic viruses. (A) Alignment of env V1/V2 T-cell tropic (top) and macrophage tropic (bottom) viruses. (B) Align-
ment of V3 T-cell tropic (top) and macrophage tropic (bottom) viruses. (C) Alignment of env V4/V5 T-cell tropic (top) and
macrophage tropic (bottom) viruses. The highlighted regions show the potential N-linked glycosylation sites within the variable
region of the envelope protein. GC6 8-4 has lost two potential N-linked glycosylation sites within V1/V2, one in V3 and two
within V4/V5 regions. The sequences derived from HC4 and GC6 8-4 clearly align with the published SI and NSI viral sequences,
respectively. This is in agreement with our phenotypic assignment of HC4 as an SI virus, and GC6 8-4 as an NSI virus.
Env sequences from HIV-1 biological clones
Figure 1 shows the variable regions (V1-V5) from HIV-1 bi-
ological clones, HC4 and GC6 8-4, aligned to SI/T-cell tropic
and NSI/macrophage tropic viruses, respectively. HIV-1 bio-
logical clone, GC6 8-4, has lost two potential N-glycosylation
sites within V1–V2, one in V3 and two within V4–V5 regions.
The V3 region derived from HC4 clearly aligns with pub-
lished SI viral sequences. This is in agreement with our phe-
notypic assignment of HC4 as an SI virus. Similarly, the V3
region of GC6 8-4 aligns with published NSI viral sequences
and agrees with our assessment of GC6 8-4 as an NSI virus.18
V3 sequences determined from chimeric viruses
Zhong et al.41 and others42 have shown a correlation between
overall amino acid change and the phenotype of HIV-1 viruses.
V3 loops of SI and NSI variants generally have an overall
charge of 1 5 and 1 3, respectively. Moreover, T-cell tropic SI
viruses generally have a basic amino acid at one or more of the
following positions: 11, 24, 25, and 32 (numbering from the
first cysteine of V3). Macrophage tropic NSI viruses have ei-
ther an acidic amino acid or alanine at position 25. The third
variable region of envelope sequenced from HIV-1 chimeric
viruses SF-G1 and SF-H2 are 35 and 38 amino acids in length,
respectively (Fig. 1B). The V3 region from HIV-1 chimeric
virus SF-H2 carries an overall charge of 1 7 with a basic amino
acid located at position 11 of the V3 loop (Fig. 1B). Zhong and
colleagues 41 report that a switch to arginine at position 11 along
with a switch to glycine at position 25 coincides with a change
from NSI to SI phenotype. The V3 region from HIV-1 chimeric
virus SF-H2 has these changes (Fig. 1B). The V3 region from
HIV-1 chimeric virus SF-G1 carries an overall charge of 1 5
with an alanine at position 25 of the V3 loop (Fig. 1B).
Phenotype of chimeric viruses
Chimeric viruses were made by removing the region from
StuI (nucleotide 6822) to NheI (nucleotide 7250) from pNL4-
3 and replacing it with the corresponding region from each bi-
ological clone (Fig. 2A). To assess if the switch in regions from
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FIG. 2. Construction of chimeric viruses, SF-G1 and SF-H2. (A) A schematic representation of the chimeric cloning strategy.
Chimeric viruses, SF-G1 and SF-H2, were constructed using the molecular clone, NL4-3, as the backbone. The 424-bp insert
that was cloned into NL4-3 was obtained by PCR from the env gene isolated from the biological clones, HC4 and GC6 8-4, and
cloned into pBluescript expression vector (p83-14 and p83-23, respectively). (B) The amino acid sequence from StuI to NheI (nu-
cleotide position 6822 to 7250, based on NL4-3 sequence) from env gene isolated from the biological clones, HC4 and GC6 8-
4, and cloned into pBluescript expression vector. The highlighted region shows the amino acids that are different between the
two chimeric viruses, SF-G1 and SF-H2. (C) The tropism, phenotype, and cytopathic profiles of the constructs. p 1 1 1 , viral
replication in T-cell lines and/or PBMC; 2 , no viral replication; # SI, syncytium-induc ing; NSI, nonsyncytium inducing; p p CP,
cytopathic in T-cell lines and PBMC; NCP, noncytopathic in T-cell lines and PBMC.
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StuI to NheI had any effect on the phenotype of the chimeric
viruses, the ability of each chimeric virus to form syncytia was
measured in a standard MT-2 assay. The removal of the region
from pNL4-3 between StuI to Nhe-I and replacem ent with the
StuI to NheI region (Fig. 2B) from HIV-1 biological clones,
HC4 and GC6 8-4, did not change the SI viral phenotype of the
parental virus, NL4-3 (Fig. 2C). Both SF-G1 and SF-H2 viruses
formed syncytia in MT-2 cells. This is in contrast to the previ-
ous result with the biological clone, GC6 8-4, which is NSI in
MT-2 cells.18
In similar assays, the chimeric viruses SF-G1 and SF-H2,
and the NL4-3 virus replicated and induced syncytia in Jurkat-
CCR5 cells. However, NL4-3 virus and SF-H2 chimeric virus
and not SF-G1 chimeric virus replicated to high titers in Jurkat
cells.
Infection of primary PBMC with chimeric HIV-1, 
SF-G1 and SF-H2
PHA-stimulated seronegative donor PBMC were infected
with HIV-1 chimeric viruses SF-H2 or SF-G1. The infection of
PBMC with the two HIV-1 chimeric viruses showed notably
different outcomes. The pattern of cell lysis in PBMC infected
with HIV-1 chimeric virus SF-H2 virus was very similar to the
control cytopathic infection with NL4-3 virus. The results were
observed for six separate experiments. On day 5 postinfection,
the mean percent viability of PBMC infected with HIV-1
chimeric virus SF-H2 was 60 ( 6 4) and PBMC infected with
NL4-3 was 62 ( 6 16) (Fig. 3a). By day 10 postinfection, 70%
of the PBMC were dead in the cultures infected with either the
HIV-1 chimeric virus, SF-H2, or the known cytopathic molec-
ular clone, NL4-3 (Fig. 3a). In contrast, PBMC infected with
SF-G1 retained a level of viability comparable to the uninfected
control cells. On day 5 postinfection, the mean percent viabil-
ity of PBMC infected with SF-G1 was 90 ( 6 2) and the unin-
fected control was 91 ( 6 1) (Fig. 3a). By day 10 postinfection,
the mean percent viability of uninfected PBMC or PBMC in-
fected with SF-G1 was 90 ( 6 1) and 80 ( 6 2), respectively (Fig.
3a).
Replication kinetics of chimeric HIV-1, SF-G1 and 
SF-H2, in PBMC
The replication kinetics of both viruses were similar to each
other as well as to NL4-3. There was a delay in viral p24 pro-
duction by HIV-1 chimeric virus SF-G1 but this was transient
FIG. 3. Viability of PBMC and CD4-enriched T cells infected with HIV-1 chimeric viruses, SF-G1 and SF-H2. Mitogen-stim -
ulated PBMC or CD4-enriched T cells were infected with titered chimeric viruses, SF-G1 and SF-H2, as described in Materials
and Methods. Cells underwent complete media change every 2 days. Percent viable cells was calculated every 2 days by trypan
blue dye exclusion. HIV-1 replication in infected PBMC and CD4 T-cell cultures was measured every 2 days by assaying cell-
free culture supernatants for HIV-1 p24 gag protein using an antigen capture ELISA. Data from eight individual experiments are
presented along with standard deviations. (a) Viability of PBMC infected with chimeric viruses, SF-G1 and SF-H2. (b) Viabil-
ity of CD4-enriched T cells infected with chimeric viruses, SF-G1 and SF-H2. (c) Replication kinetics of chimeric viruses, SF-
G1 and SF-H2, in infected CD4-enriched T cells.
and eventually the viral replication was equivalent to that of
SF-H2 and NL4-3. These results were observed for six sepa-
rate experim ents. On day 5 postinfection, the mean p24 assayed
from the cultures infected with HIV-1 chimeric viruses, SF-H2
and SF-G1, was 120 ( 6 119) and 49 ( 6 94) ng/ml, respectively.
By day 7 postinfection, the mean p24 assayed from the cultures
infected with HIV-1 chimeric viruses, SF-G1 and SF-H2, was
148 ( 6 54) and 206 ( 6 81) ng/ml, respectively.
Infection of CD4-enriched T cells with chimeric 
HIV-1, SF-G1 and SF-H2
CD4-enriched T cells were infected with HIV-1 chimeric
virus SF-H2 or HIV-1 chimeric virus SF-G1. The infection of
CD4-enriched T cells with the two chimeric viruses showed no-
tably different outcomes. The pattern of cell destruction in CD4-
enriched T cells infected with HIV-1 chimeric virus SF-H2 was
very similar to the control cytopathic NL4-3 virus. On day 5
postinfection, the mean percent viability (obtained from eight
separate experiments) of CD4-enriched  T cells infected with
SF-H2 was 53 ( 6 2) and CD4 enriched T cells infected with
NL4-3 was 52 ( 6 5) (Fig. 3b). By day 7 postinfection, approx-
imately 70% of the CD4-enriched T cells were dead in the cul-
tures infected with either HIV-1 chimeric virus SF-H2 or NL4-
3 (Fig. 3b). However, HIV-1 chimeric virus SF-G1 was
phenotypically different from SF-H1. On day 5 postinfection,
the mean percent viability of CD4-enriched T cells infected with
HIV-1 chimeric virus SF-G1 was 89 ( 6 4) and the uninfected
control was 91 ( 6 2) (Fig. 3b). By day 7 postinfection, ap-
proximately 90% of the CD4-enriched  T cells were viable from
cultures either uninfected or infected with HIV-1 chimeric virus
SF-G1 (Fig. 3b).
Replication kinetics of chimeric HIV-1, SF-G1 and 
SF-H2, in CD4-enriched T cells
The replication kinetics of both viruses were similar to the
NL4-3 virus. There was a delay in viral p24 production by HIV-
1 chimeric virus SF-G1 but this was transient and by day 7, SF-
G1 viral replication (132 6  63 ng/ml) was equivalent to that of
HIV-1 chimeric virus SF-H2 (186 6  18 ng/ml) and NL4-3 (Fig.
3c). By day 10 postinfection, the mean p24 assayed from the
cultures infected with HIV-1 chimeric viruses, SF-H2 and SF-
G1, was 617 ( 6 158) and 580 ( 6 40) ng/ml, respectively (Fig.
3c). These results were observed for eight separate experiments.
Viral infection was also assessed by measuring the amount of
proviral DNA. Quantitative DNA PCR analysis demonstrated
that the proviral copy numbers were similar in CD4-enriched
T cells infected with either HIV-1 chimeric virus SF-H2 or HIV-
1 chimeric virus SF-G1 (data not shown).
Outcome of CD4 T cells infected with chimeric HIV-1,
SF-G1 and SF-H2
To determ ine the fate of CD4-enriched T cells infected with
HIV-1 chimeric viruses, SF-G1 and SF-H2, flow cytometric
analyses were performed on cells removed from the infected
cultures at days 3, 5, 7, and 10 postinfection. The percentage
of CD4 T cells in uninfected and HIV-1 biological clone in-
fected cultures was determ ined by flow cytometry (Fig. 4). The
percentage of CD4 T cells in HIV-1 chimeric SF-H2-infected
cultures dramatically declined over 5 to 7 days postinfection.
Between days 3 and 5 postinfection, CD4 T cells declined from
82 to 21% (Fig. 4d). By day 7 postinfection, the percentage of
CD4 T cells decreased to 15 and by day 10 the culture was
completely dead. In contrast, by day 5 postinfection, there was
82% CD4 T cells in HIV-1 chimeric virus SF-G1 infected cul-
tures (Fig. 4b), and 90% CD4 T cells in the uninfected culture
(Fig. 4a). The cells in the lower left quadrant represent viable
T cells that have down-regulated their CD4 antigen expression
due to viral infection. On day 7 postinfection, 72% of T cells
in HIV-1 chimeric virus SF-G1 infected culture expressed CD4
antigen and 20% of viable T cells had down-regulated their ex-
pression of CD4 antigen.
Infection of Jurkat-CCR5 cells with the chimeric
viruses, SF-G1 and SF-H2
To address the question of whether the chimeric virus, SF-
G1 was truly attenuated or whether the HIV-1-induce d cell ly-
sis was delayed, we used a T-cell line, Jurkat-CCR5. One lim-
itation with the use of CD8-depleted PBMC cultures is that the
life of these cells in vitro is very short (10–12 days) compared
with T-cell lines that are adapted for culture and can be kept in
culture indefinitely. Jurkat-CCR5 T cells were infected with
HIV-1 chimeric virus SF-H2 or HIV-1 chimeric virus SF-G1.
The infection of Jurkat-CCR5 T cells with the two chimeric
viruses showed notably different outcomes. The pattern of cell
destruction in Jurkat-CCR5 T cells infected with HIV-1
chimeric virus SF-H2 was very similar to the control cytopathic
NL4-3 virus. On day 8 postinfection, the percent viability of
Jurkat-CCR5 T cells infected with SF-H2 was 56% and Jurkat-
CCR5 T cells infected with NL4-3 was 46% (Fig. 5a). The vi-
ral replication on day 8 postinfection, as measured by p24 anti-
gen production, was equivalent for all the three viruses, NL4-3,
SF-H2, and SF-G1 (186, 230, and 317 pg/ml, respectively (Fig.
5b). Viral replication peaked on day 10 with cultures infected
with NL4-3, (1178 ng/ml), SF-H2 (1486 ng/ml), and SF-G1
(1141 ng/ml) producing equivalent amounts of p24 antigen (Fig.
5b). By day 13 postinfection, approximately 80% of the Jurkat-
CCR5 T cells were dead in the cultures infected with either
HIV-1 chimeric SF-H2 or NL4-3 (Fig. 5a). The cultures in-
fected with either SF-H2 or NL4-3 were completely dead by
day 17 postinfection. In contrast, infection of Jurkat-CCR5 T-
cells with HIV-1 chimeric virus SF-G1 produced different re-
sults. The differences between the uninfected control and those
T cells infected with SF-G1 were observed early in the course
of the infection. Between days 8 and 15 postinfection, the via-
bility of T cells infected with SF-G1 ranged from 65% (day 8)
to 60% (day 15). During this time many syncytia were observed
in the cultures infected with NL4-3, SF-H2, and SF-G1. Inter-
estingly, on day 17 postinfection the cultures infected with SF-
G1 began to recover and 74% of the T cells were viable (Fig.
5a). On day 22 postinfection, the percent viability of Jurkat-
CCR5 T cells infected with HIV-1 chimeric virus SF-G1 was
90% as was the uninfected control (Fig. 5a). From day 20
through the end of the experiment on day 38, the culture in-
fected with SF-G1 continued to produce virus (figure 5b). On
day 39 postinfection when the experiment was terminated, 97%
of the Jurkat-CCR5 T cells were viable from cultures either un-
infected or infected with HIV-1 chimeric virus SF-G1 (Fig. 5a).
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On day 24 of the infection, cell-free viral supernatant from the
SF-G1 culture, now termed SF-G1R1, was used to infect new
Jurkat-CCR5 T cells. Between days 3 (day 27) and 6 (day 33)
postinfection, the viability of T cells reinfected with SF-G1R1
ranged from 75% (day 29) to 60% (day 33) (Fig. 5a). During
this period many syncytia were observed in the cultures. Inter-
estingly, on day 7 postinfection with SF-G1R1 the infected cul-
tures began to recover and 75% of the T cells were viable (SF-
G1R1, Fig. 5a). On day 13 postinfection, the percent viability
of Jurkat-CCR5 T cells reinfected with HIV-1 chimeric virus
SF-G1 was 89% (SF-G1R1, Fig. 5a).
DISCUSSION
In this study we genetically analyzed a specific region within
HIV-1 envelope (nucleotide positions 6822 to 7250) from a cy-
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FIG. 4. CD4-enriched T cells infected with the chimeric virus, SF-G1, retain viable CD4-positive cells. Two-color flow cytome-
try analysis of CD4-enriched T cells uninfected or infected with either NL4-3 virus or chimeric viruses, SF-G1 and SF-H2. Cells
were harvested on days 3, 5, 7, and 10 postinfection, stained for both CD4 and CD8, fixed in paraformaldehyde, and analyzed by
flow cytometry. (a) Uninfected. (b) Chimeric virus, SF-G1. (c) Chimeric virus, SF-H2. (d) Molecular virus clone, NL4-3.
topathic and a noncytopathic biological clone by generating
chimeric viruses with the well-characteriz ed molecular clone,
NL4-3. The most striking difference between these chimeric
viruses when compared to each other as well as NL4-3 was that
SF-G1, the chimeric virus containing a downstream V2 and V3
region of the noncytopathic envelope, was attenuated for cyto-
pathicity. This switch in cytopathicity held true in PBMC as
well as in T-cell lines (Figs. 3 and 5).
In general, viruses that infect macrophages are restricted in
their ability to infect T-cell lines. It has been shown that viruses
isolated early in infection are NSI and macrophage tropic, while
viruses recovered from individuals with low CD4 T-cell counts
are generally SI with the ability to replicate in T-cell lines.1–4
When the phenotype of each chimeric virus was assessed it was
found to be identical to the parental virus NL4-3, which is SI.
The chimeric viruses, SF-G1 and SF-H2, were both SI despite
different V3 signature sequences that predicted that SF-G1
would be NSI and SF-H2 would be SI. The V3 region sequenced
from SF-H2 has classic SI hallmarks, such as increased charge
( 1 7, Fig. 1B) and a switch from an arginine at position 11 along
with a switch to glycine at position 25 (Fig. 1B). The predicted
phenotype based solely on the V3 sequence of SF-H2 is SI. The
results are in agreement with this prediction (Fig. 2C). At all
stages in the viral population, i.e., quasispecies, 17 biological
clone,18 and chimeric virus (this report), the predicted pheno-
type was the determined phenotype. In contrast, the V3 region
sequenced from SF-G1 showed features attributed to viruses
having an NSI phenotype, such as an overall change of 1 5 with
an alanine at position 25 of the V3 loop (Fig. 1B). Therefore,
the predicted phenotype, based solely on the V3 sequence of
SF-G1, was NSI. SF-G1 chimeric virus replicated to high titers
in Jurkat-CCR5 T cells and not in Jurkat T cells. The pheno-
type of the patient A quasispecies was NSI17 as was the phe-
notype of the biological clone isolated from the quasispecies. 18
Although the chimeric clone SF-G1 preferentially used the
CCR5 coreceptor the phenotype of the SF-G1 virus was SI (Fig.
2C). These results contrast with previous published observa-
tions30,31 that show that mutations within the envelope gene
(gp120), allowing an SI phenotype, are capable of increasing
cytopathicity. However, these data are consistent with the re-
cent published observation in the SIV system.1 Kimata and
Overbaugh showed that the minimal region of SIV responsible
for syncytium formation mapped to the envelope gene.52 Even
though the phenotype of the chimeric SIV env was SI it did not
increase the cytopathicity in either CEM 3 174 or macaque
PBMC. Other variable regions besides V3 have been suggested
to play a role in HIV cytopathicity. It has been shown that en-
velope glycoproteins that contain either site-directed mutations
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FIG. 5. Viability of Jurkat-CCR5 cells infected with HIV-1 chimeric viruses, SF-G1 and SF-H2. Jurkat-CCR5 cells were in-
fected with titered chimeric viruses, SF-G1 and SF-H2, as described in Materials and Methods. Cells underw ent complete me-
dia change every 2 days. On day 24 of the infection, cell-free viral supernatant from the SF-G1 culture, now termed SF-G1R1,
was used to infect fresh Jurkat-CCR5 cells. Percent viable cells was calculated every 2 days by trypan blue dye exclusion. HIV-
1 replication in infected Jurkat-CCR5 cultures was measured every 2 days by assaying cell-free culture supernatants for HIV-1
p24 gag protein using an antigen capture ELISA. Data from one representative experiment are presented. (a) Viability of Jurkat-
CCR5 cells infected with chimeric viruses, SF-G1 and SF-H2. On day 24 of the infection, cell-free viral supernatant from the
SF-G1 culture, now termed SF-G1R1, was used to infect fresh Jurkat-CCR5 cells. (b) Replication kinetics of chimeric viruses,
SF-G1 and SF-H2, in Jurkat-CCR5 T cells.
within the V1/V2 region 43,44 or V1/V2 regions containing
chimeric V2 sequences exhibit altered cytopathicity. 45 –47 Sul-
livan and co-workers demonstrated that specific amino acids
mutations in the tip of V2 yielded fusion defective viruses.44
In addition, all of the mutant V1/V2 envelope glycoproteins dis-
played decreased syncytium -inducing abilities, with some mu-
tants lacking the ability to induce cell fusion altogether. Taken
together, these results demonstrate that the third variable region
of envelope is not the only region involved in syncytium for-
mation. Moreover, the formation of syncytium does not neces-
sarily dictate cell death (Fig. 5). In other words, the NSI/SI phe-
notype does not correlate with the NCP/CP phenotype. These
results further support previous observations that HIV-1-in-
duced single cell killing is independent of syncytium forma-
tion.48
Differences in HIV-1 viral tropism, phenotype, and replica-
tion kinetics have been assigned to the envelope surface gly-
coprotein. 30,31 Along with these properties, studies of mutant
HIV-1 viruses have provided evidence that a major determinant
for cell killing maps to the viral envelope glycoproteins. For
these reasons, prior to analyzing these subgenomic fragments,
we attempted to construct full-length env chimeric viruses by
replacing the env region from NL4-3 with either the HC4 or
GC6 8-4 env gene. The many attempts using standard cloning
techniques, in vitro recombination, and advanced cloning tech-
niques failed to develop a stable full length functional envelope
product. For reasons we can not explain, envelope genes iso-
lated from these biological clones are extremely unstable.
The molecular mechanism(s)  of HIV-1-induced  cell lysis is
likely to be multifactorial. Experiments with mutant HIV-1
viruses do not unequivocally resolve the role of viral accessory
proteins (Vif, Vpr, Tat, Nef ) in HIV-1 cell killing.49 –51 Cheng-
Mayer and colleagues concluded from their observations with
recombinant viruses that the envelope region contains the ma-
jor determinants of HIV-1 cytopathicity. 32 Stevenson et al.34
reported that two amino acid changes within gp120 altered the
efficiency of processing of the gp160 envelope glycoprotein
precursor, which in turn decreased the ability of a replication-
competent HIV-1 virus to induce single cell lysis. Kowalski et
al.33 showed that a mutation within the gp41 amino terminus
of envelope, which generated a replication-com petent noncy-
topathic virus, was attenuated in its ability to form syncytia and
to induce single cell death. Cao et al.35 described an inducible
system to examine envelope-induced single cell lysis. Their
studies demonstrated that the ability of HIV-1 envelope glyco-
proteins to mediate membrane fusion was obligatory for both
syncytium formation and single cell lysis.
Our results demonstrate that the cytopathic profile of NL4-
3 can be altered by a specific disruption of the envelope se-
quences contained within the downstream region of V2 and
within the V3 region (nucleotide positions 6822 to 7250). In-
terestingly, disrupting this region by inserting the same region
from a cytopathic biologically cloned virus (HC4) did not alter
the ability of the parental virus to induce cell death (Fig. 2). It
was only when that region was disrupted with the insertion of
the same region from a noncytopathic biologically cloned virus
(SF-G1) did the cytopathic profile change (Fig. 2). These re-
sults suggest that it is not just the disruption of that region but
the disruption of that region by a specific sequence, which at-
tenuates the cytopathic profile of the parental virus. The pre-
cise role of these specific sequences in cytopathicity and core-
ceptor usage will be further analyzed using detailed mutagen-
esis studies that are underway.
Cao et al.35 and others31–34 have shown that differences in
HIV-1 cytopathicity can be mapped to mutations within the en-
velope glycoproteins. Recent observations regarding SIV-in-
duced cytopathicity have reached similar conclusions. Kimata
and Overbaugh 52 showed that SIV-induced cytopathicity is de-
termined by mutations in gag and env genes. Karlsson et al.53
using passaged recombinant SHIV-89.6P viruses constructed
between SIV (SIVm ac239) and HIV-1 (89.6) showed that
changes within the 3 9 half of the SHIV-89.6P genome that oc-
curred within the envelope gene were responsible for increased
cytopathicity. Taken together, these findings, along with those
reported herein, support the hypothesis that the HIV-1 envelope
glycoprotein plays a role in HIV-1-induced  cytopathicity. Fur-
ther studies addressing the role of envelope in HIV-1-induced
cell killing are necessary to understand the specific molecular
mechanism(s) involved in CD4 T-cell depletion in AIDS patho-
genesis.
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